<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Discov Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Discov Oncol</journal-id><journal-id journal-id-type="pmc-domain-id">4139</journal-id><journal-id journal-id-type="pmc-domain">discon</journal-id><journal-title-group><journal-title>Discover Oncology</journal-title></journal-title-group><issn pub-type="epub">2730-6011</issn><publisher><publisher-name>Springer</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11890481</article-id><article-id pub-id-type="pmcid-ver">PMC11890481.1</article-id><article-id pub-id-type="pmcaid">11890481</article-id><article-id pub-id-type="pmcaiid">11890481</article-id><article-id pub-id-type="pmid">40056282</article-id><article-id pub-id-type="doi">10.1007/s12672-025-01864-1</article-id><article-id pub-id-type="publisher-id">1864</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Real world experience with MET inhibitors in MET exon 14 skipping mutated non-small cell lung cancer: largest Indian perspective</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Batra</surname><given-names initials="U">Ullas</given-names></name><address><email>ullasbatra@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Singh</surname><given-names initials="AK">Ajay Kumar</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nathany</surname><given-names initials="S">Shrinidhi</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Dewan</surname><given-names initials="A">Abhinav</given-names></name><address><email>abhinavdewan25@gmail.com</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sharma</surname><given-names initials="M">Mansi</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Amrith</surname><given-names initials="BP">B. P.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mehta</surname><given-names initials="A">Anurag</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Batra</surname><given-names initials="V">Vanshika</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Noronha</surname><given-names initials="V">Vanita</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Prabhash</surname><given-names initials="K">Kumar</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00e7cvg05</institution-id><institution-id institution-id-type="GRID">grid.418913.6</institution-id><institution-id institution-id-type="ISNI">0000 0004 1767 8280</institution-id><institution>Medical Oncology, </institution><institution>Rajiv Gandhi Cancer Institute and Research Center, </institution></institution-wrap>Sector-5, Rohini, New Delhi, 110085 India </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/010842375</institution-id><institution-id institution-id-type="GRID">grid.410871.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 1769 5793</institution-id><institution>Medical Oncology, </institution><institution>Tata Memorial Hospital, </institution></institution-wrap>Mumbai, India </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01h7phh70</institution-id><institution-id institution-id-type="GRID">grid.464839.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 4653 2037</institution-id><institution>Molecular Hematology &amp; Oncology, </institution><institution>Fortis Memorial Research Institute, </institution></institution-wrap>Gurugram, Haryana India </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00e7cvg05</institution-id><institution-id institution-id-type="GRID">grid.418913.6</institution-id><institution-id institution-id-type="ISNI">0000 0004 1767 8280</institution-id><institution>Medical Oncology, </institution><institution>Rajiv Gandhi Cancer Institute and Research Center, </institution></institution-wrap>New Delhi, India </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00e7cvg05</institution-id><institution-id institution-id-type="GRID">grid.418913.6</institution-id><institution-id institution-id-type="ISNI">0000 0004 1767 8280</institution-id><institution>Molecular Diagnostics, </institution><institution>Rajiv Gandhi Cancer Institute and Research Center, </institution></institution-wrap>New Delhi, India </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04kf25f32</institution-id><institution-id institution-id-type="GRID">grid.449187.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 4655 4957</institution-id><institution>SGT Medical College, </institution></institution-wrap>Gurugram, Haryana India </aff></contrib-group><pub-date pub-type="epub"><day>8</day><month>3</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2025</year></pub-date><volume>16</volume><issue-id pub-id-type="pmc-issue-id">478248</issue-id><elocation-id>286</elocation-id><history><date date-type="received"><day>10</day><month>9</month><year>2024</year></date><date date-type="accepted"><day>3</day><month>2</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>08</day><month>03</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>09</day><month>03</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-03-10 16:25:39.000"><day>10</day><month>03</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="12672_2025_Article_1864.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Patients with Non-small Cell Lung Cancer (NSCLC) presenting with Mesenchymal&#8211;epithelial transition exon 14 skipping mutation (MET ex14) have an unfavorable prognosis with traditional therapies. MET inhibitors have altered the therapeutic paradigm of NSCLC. MET ex14 skipping alteration is reported in 3&#8211;4% cases (N Engl J Med 383(10):944-957, 2020, Cancer Discov 5(8):842-9, 2015). Randomized controlled trials have reported noteworthy outcomes of selective MET tyrosine kinase inhibitors (TKIs), however real-world data from the Indian sub-continent is lacking.</p></sec><sec><title>Methods</title><p id="Par2">The current study is a non-interventional retrospective multi-centre analysis reporting on real-world data of NSCLC patients with MET ex14 skipping alteration from two apex cancer centers from India. Data of 49 eligible NSCLC patients with MET ex14 mutations fulfilling the inclusion and exclusion criteria were reviewed and analysed. Kaplan Meier (KM) estimating method was used to estimate the overall survival (OS) and progression free survival (PFS). Log rank test was used to compare the survival curves between the groups. A p-value&#8201;&lt;&#8201;0.05 was considered clinically significant. Statistical analysis was performed using R studio.</p></sec><sec><title>Results</title><p id="Par3">A total of 49 patients harboring MET ex14 alterations were included in the current study. Table <xref rid="Tab1" ref-type="table">1</xref>. shows the clinico-pathological features of these patients. Treatment patterns were heterogeneous across therapy lines and included systemic therapy, MET TKIs and immunotherapy. Approximately 85.71% (42/49) patients opted for treatment. First line TKIs were offered to 14 patients; while chemotherapy was given to 28 patients. First-line TKIs doubled the PFS in comparison to chemotherapy arm (mPFS: 11.9&#160;months vs. 5.9&#160;months, p&#8201;&lt;&#8201;0.002*, HR for TKI: 0.3295. On multivariate analysis, male sex and TP53 co-mutation were factors influencing the first-line PFS (p&#8201;&lt;&#8201;0.06). Second line treatment was taken by 13/14 patients in the TKI arm of which 5 received sequential TKI, while 8 received chemotherapy. Similarly, 22/28 patients in the chemotherapy arm received second line treatment. Of these 22 patients, 14 received sequential TKIs, while 8 received next line systemic chemotherapy (TKIs: 14, chemotherapy: 8). PFS for 2nd line TKI was 7.7&#160;months (95% CI, 2.8&#8211;14.8) vs. 4.6&#160;months (95% CI,&#160;2.1&#8211;9.8) for chemotherapy arm (HR for TKI: 0.3641, p&#8201;&lt;&#8201;0.04*). Around 57% (28/49) received MET TKI therapy at any given time point during the disease course. Median OS for patients treated with 1st line TKI and systemic chemotherapy was not reached (95% CI 9.2-NR months) and 20.7&#160;months (95% CI 18.1&#8211;36.1&#160;months) respectively at the study endpoint (p&#8201;=&#8201;0.3).<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table&#160;1</label><caption><p>Characteristics of the patients at baseline</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Clinicopathological Features</th><th align="left" colspan="1" rowspan="1">n&#8201;=&#8201;49</th><th align="left" colspan="1" rowspan="1">%</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Age (Years)</td><td align="left" colspan="1" rowspan="1">Median: 70 (Range, 39&#8211;85)</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">ECOG PS</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;1</td><td align="left" colspan="1" rowspan="1">40</td><td align="left" colspan="1" rowspan="1">81.6</td></tr><tr><td align="left" colspan="1" rowspan="1"><underline>&#160;&#8805;</underline>2</td><td align="left" colspan="1" rowspan="1">9</td><td align="left" colspan="1" rowspan="1">18.4</td></tr><tr><td align="left" colspan="1" rowspan="1">Gender</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Male</td><td align="left" colspan="1" rowspan="1">33</td><td align="left" colspan="1" rowspan="1">67.3</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Female</td><td align="left" colspan="1" rowspan="1">16</td><td align="left" colspan="1" rowspan="1">32.7</td></tr><tr><td align="left" colspan="1" rowspan="1">Smoking Status</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Ever smoker</td><td align="left" colspan="1" rowspan="1">34</td><td align="left" colspan="1" rowspan="1">69.3</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Never smoker</td><td align="left" colspan="1" rowspan="1">15</td><td align="left" colspan="1" rowspan="1">30.7</td></tr><tr><td align="left" colspan="1" rowspan="1">Brain metastases</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Present at diagnosis</td><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">8.3</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Developed Later</td><td align="left" colspan="1" rowspan="1">12</td><td align="left" colspan="1" rowspan="1">24.4</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Absent</td><td align="left" colspan="1" rowspan="1">33</td><td align="left" colspan="1" rowspan="1">67.3</td></tr><tr><td align="left" colspan="1" rowspan="1">Histology</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Adenocarcinoma</td><td align="left" colspan="1" rowspan="1">33</td><td align="left" colspan="1" rowspan="1">67.3</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Squamous cell carcinoma</td><td align="left" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">16.3</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Adenosquamous carcinoma</td><td align="left" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">16.3</td></tr><tr><td align="left" colspan="1" rowspan="1">Co-mutations</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;<italic toggle="yes">TP53</italic></td><td align="left" colspan="1" rowspan="1">12</td><td align="left" colspan="1" rowspan="1">24.4</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;<italic toggle="yes">KRAS</italic></td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">2.1</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;<italic toggle="yes">CTNNB1</italic></td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">2.1</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;<italic toggle="yes">MET</italic> Copy number gain</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">2.1</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;None</td><td align="left" colspan="1" rowspan="1">34</td><td align="left" colspan="1" rowspan="1">69.3</td></tr><tr><td align="left" colspan="1" rowspan="1">PDL1</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8201;&#160;&lt;&#8201;1%</td><td align="left" colspan="1" rowspan="1">9</td><td align="left" colspan="1" rowspan="1">18.4</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;1&#8211;49%</td><td align="left" colspan="1" rowspan="1">20</td><td align="left" colspan="1" rowspan="1">40.8</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8201;&#160;&gt;&#8201;49%</td><td align="left" colspan="1" rowspan="1">20</td><td align="left" colspan="1" rowspan="1">40.8</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">MET</italic> exon 14 skipping</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;DNA only</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">0</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;RNA only</td><td align="left" colspan="1" rowspan="1">30</td><td align="left" colspan="1" rowspan="1">61.2</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Both DNA &amp; RNA</td><td align="left" colspan="1" rowspan="1">19</td><td align="left" colspan="1" rowspan="1">38.8</td></tr></tbody></table></table-wrap></p></sec><sec><title>Conclusion</title><p id="Par4">The current study comprises of the largest MET ex14 mutated NSCLC patient cohort reporting on the real-world data of MET TKI therapy from the Indian subcontinent. MET TKI showed higher systemic and intracranial efficacy with manageable safety profile. The current study represents an unmet need for more clinical phase 3 study for rare genomic alterations as well as patient access programs in the Indian subcontinent.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>MET ex14</kwd><kwd>Real-world data</kwd><kwd>TKI</kwd><kwd>Indian subcontinent</kwd><kwd>Unmet need</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Science+Business Media LLC, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">National Comprehensive Cancer Network (NCCN) mandates next generation sequencing (NGS) based molecular profiling for all Non-small cell lung cancer (NSCLC) patients which has aided in increased biomarker detection. Apart from the canonical Epidermal growth factor receptor (<italic toggle="yes">EGFR),</italic> Anaplastic lymphoma kinase (ALK) and ROS proto-oncogene 1 (<italic toggle="yes">ROS1</italic>) mutations detected on single gene testing, newer biomarkers have been discovered and approval of small molecule inhibitors for the same have transformed the therapeutic paradigm of NSCLC patients [<xref ref-type="bibr" rid="CR1">1</xref>].</p><p id="Par6">Protooncogenes are regulatory factors involved in various biological processes and are present in normal cells of the body. They tend to encode proteins that function as growth factors, cell-signalling transducers, transcriptional factors, stimulate cell division, inhibit cell differentiation impede cell death. Modification of protooncogene is typically&#160;dominant&#160;and is called as an oncogene. Oncogenes demonstrate increased production of protooncogene encoded proteins, thereby playing a pivotal role in the pathogenesis of cancer. One such protooncogene is Mesenchymal epithelial transition (MET) protooncogene [<xref ref-type="bibr" rid="CR2">2</xref>].</p><p id="Par7">MET protooncogene encodes receptor tyrosine kinase on the epithelial cells which in turn promotes tissue proliferation. Aberrant MET pathway leads to increased cell proliferation, survival, invasion and metastasis. MET pathway activation is associated with various malignancies and is caused by gene amplification, overexpression or MET exon 14 skipping mutations (<italic toggle="yes">MET</italic> ex14). Traditionally, absence of biomarkers made it challenging to identify patients benefiting from MET-specific therapy. Treatment based on MET overexpression has not shown any potential benefit. In contrast, MET amplifications and MET exon 14 skipping mutations have appeared as important predictive biomarkers [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>].</p><sec id="Sec2"><title>MET exon 14 skipping mutation (MET ex14)</title><p id="Par8"><italic toggle="yes">MET</italic> ex14 has been reported in 3&#8211;4% NSCLC, with variations in different histologic subtypes [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. The highest prevalence is seen in the&#160;sarcomatoid histology (4.9&#8211;31%) when compared to adenocarcinoma (3&#8211;4%) and squamous&#160;histology (2%) [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. It can occur due to point mutations or from insertions and deletions. The shorter exon 14&#8212;spliced protein has improved stability, which tends to further amplify MET signalling and is associated with unfavorable prognosis. It is mutually exclusive with other oncogene drivers and tends to occur more commonly in elderly patients, especially those who smoke [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. The approval of <italic toggle="yes">MET</italic> selective TKIs: Capmatinib (Recommended Dose: 400&#160;mg twice a day) and Tepotinib (Recommended Dose: 450&#160;mg once a day) have shown a durable clinical benefit in controlled trials GEOMETRY Mono-I study (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02414139">NCT02414139</ext-link>) and VISION study (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02864992">NCT02864992</ext-link>), respectively [<xref ref-type="bibr" rid="CR8">8</xref>].</p><p id="Par9">Various small molecule tyrosine kinase inhibitors (TKIs) compete with ATP to block the phosphotransferase activity of the MET target. These molecules can be classified into selective (Tepotinib, Savolitinib, Capmatinib) and non-selective TKIs (Crizotinib). Capmatinib is a potent and selective small molecule MET inhibitor with substantial antitumor activity in malignancies with MET activation. Capmatinib has the ability to cross the blood&#8211;brain barrier and shows significant intracranial efficacy. Preliminary data shows promising efficacy at low toxicity in MET dysregulated NSCLC patients [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR8">8</xref>&#8211;<xref ref-type="bibr" rid="CR10">10</xref>]. Tepotinib is an another once-daily, highly selective oral MET inhibitor with promising clinical efficacy [<xref ref-type="bibr" rid="CR8">8</xref>].</p><p id="Par10">Despite the rapid approvals of TKIs, the selection of appropriate therapy for this subgroup of patients remains a challenge. Real-life data of MET exon 14 mutated patients treated with MET inhibitors is scarce. This may be attributed to the rarity of occurrence, elderly patient population, recent recognition of MET exon 14 skipping mutation as an oncogene driver and unavailability of selective TKIs for the population at large, especially in economically restrained setups like India. Therefore, there exists a knowledge gap due to the limited experience with these drugs. In addition, there is a&#160;need for additional real-world data particularly for patients with poorer PS and elderly population.</p><p id="Par11">This study is a retrospective pooled real-world experience of the subgroup of the patients, depicting the glaring disparities in cancer care delivery in this part of the world owing to the&#160;lack of accessibility to newer small molecular inhibitors/ global clinical trials.</p></sec></sec><sec id="Sec3"><title>Methods</title><sec id="Sec4"><title>Patient characteristics</title><p id="Par12">This is a retrospective pooled real-world experience of Stage IV lung cancer patients with MET ex14, registered at two apex cancer hospitals of India, Rajiv Gandhi Cancer Institute and Research Center, New Delhi and Tata Memorial Hospital, Mumbai. A total of 49 patients were identified and the study&#160;design is depicted in Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>. The clinical and pathological information of the patients were collated through electronic medical records of both the centers. The inclusion criteria included histology proven Stage IV Non-small cell lung cancer of any histological subtype, age&#8201;&#8805;&#8201;18&#160;years, harboring confirmed MET ex14 alteration and treated with MET TKI in any line. The study has been carried out in accordance with Declaration of Helsinki. No animal subjects have been used/harmed. The ethics for the study was approved by the Institutional review board of Rajiv Gandhi Cancer Institute and Research Centre, Delhi (IRB Number). Informed consent has been waived by Rajiv Gandhi Cancer Institute and Research centre, New Delhi.<fig id="Fig1" position="float" orientation="portrait"><label>Fig.&#160;1</label><caption><p>Study Design: Consort diagram of 49 patients with MET exon 14 skipping Mutations</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="12672_2025_1864_Fig1_HTML.jpg"/></fig></p></sec><sec id="Sec5"><title>Endpoint</title><p id="Par13">Primary end point of the study was the PFS, OS and adverse effects. The progression free survival (PFS) was calculated form the date of start of treatment up to the date of documented progression/death/change of treatment for any reason. The overall survival (OS) was calculated from date of diagnosis to last date of follow up/death.</p></sec><sec id="Sec6"><title>Statistical analysis</title><p id="Par14">This is a descriptive study aimed at depicting the molecular epidemiology and clinical features of MET ex14 mutated NSCLC in an Indian cohort. However, indicators including incidence and prevalence could not be calculated as this is an enriched population of those patients who underwent NGS based testing and is not representative of the population at risk. Continuous variables were expressed as median and categorical variables as frequencies (%). Kaplan Meier (KM) estimating method was used to estimate the overall survival (OS) and progression free survival (PFS). Log rank test was used to compare the survival curves between the groups [<xref ref-type="bibr" rid="CR10">10</xref>]. All analysis was carried out using MedCalc QC (Ostend, Belgium) software and images were generated using R studio. A two tailed p value of&#8201;&lt;&#8201;0.05 was considered statistically significant.</p></sec></sec><sec id="Sec7"><title>Results</title><sec id="Sec8"><title>Patient demographics</title><p id="Par15">A total of 49 patients harboring <italic toggle="yes">MET</italic> ex14 mutations were included in the present study. Median age of the cohort was 70&#160;years (Range: 39&#8211;85&#160;years). There was a clear male predilection with a male to female ratio of 2.06:1. Majority of the patients had an ECOG PS of&#8201;&#8805;&#8201;1. Table <xref rid="Tab1" ref-type="table">1</xref> shows the baseline clinicopathological characteristics of these patients.</p></sec><sec id="Sec9"><title>MET alterations</title><p id="Par16"><italic toggle="yes">MET</italic> exon 14 mutation was detected only in the RNA assay in 30 (61.2%) cases as a true and valid call with&#8201;&#8805;&#8201;1000 fusion mapping reads. Both DNA and RNA were positive in 19 (38.8%) cases. This may be attributed to the assay design which is employed in most NGS centers. The off the shelf commercially available targeted cancer panel do not have primer sets to cover the 5&#8217; region of exon 14 of the <italic toggle="yes">MET</italic> gene, leading to false negatives on DNA based NGS. In terms of co-mutations, <italic toggle="yes">TP53</italic> was the most common co-mutation and was detected in 12 (24.4%) cases, followed by <italic toggle="yes">KRAS</italic> and <italic toggle="yes">CTNNB1</italic> in 1 (2.04%) case each. <italic toggle="yes">MET</italic> copy number gain was observed in 1 (2.04%) case with 12.7 copies of <italic toggle="yes">MET</italic> gene.</p></sec><sec id="Sec10"><title>Treatment details</title><p id="Par17">Treatment patterns were variable across therapy lines. They included systemic therapies, immunotherapy and TKIs. Majority of the patients (42/49, 85.71%) decided to proceed with further treatment. First line TKIs were offered to 14/42 (33.33%) patients, while systemic therapy was offered to 28/42 (66.67%) patients. In the TKI arm, second line treatment was opted for by 13/14 (92.86%) patients of which 5/13 (38.46%) received sequential TKI, and 8/13 (61.54%) received chemotherapy. In the chemotherapy arm, 22/28 (78.57%) opted for the&#160;next line treatment (TKI: 14/22, Systemic chemotherapy: 8/22). Approximately half of the patients [28/49 (57.14%)] received MET TKI based therapy at a given point during their disease course.</p></sec><sec id="Sec11"><title>Intracranial response</title><p id="Par18">A total of 16 patients with NSCLC with a MET exon 14 skipping mutation had brain metastases either at baseline (4/16) or developed later during the course of treatment (12/16). A total of 12 of the 16 patients had intracranial disease control according to neuroradiologic assessment. Patients with brain metastasis had an inferior survival in comparison to those without (TKI: mPFS 11.4&#160;months vs. 17.8&#160;months, p&#8201;=&#8201;0.1; Chemotherapy: mPFS 5.4 vs. 5.9&#160;months, p&#8201;=&#8201;0.9 (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table&#160;2</label><caption><p>Multivariate analysis of factors affecting PFS</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Clinical features</th><th align="left" colspan="1" rowspan="1">TKI (n&#8201;=&#8201;14)</th><th align="left" colspan="1" rowspan="1">Chemotherapy (n&#8201;=&#8201;28)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Age</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8201;&#160;&lt;&#8201;65</td><td align="left" colspan="1" rowspan="1">11.4&#160;m (95% CI 8.8&#8211;11.43)</td><td align="left" colspan="1" rowspan="1">5.9&#160;m (95% CI 2.7&#8211;13.9)</td></tr><tr><td align="left" colspan="1" rowspan="1"><underline>&#160;&#8805;</underline>65</td><td align="left" colspan="1" rowspan="1">11.3&#160;m (95% CI 3.8&#8211;16.43)</td><td align="left" colspan="1" rowspan="1">4.7&#160;m (95% CI 2.7&#8211;16.7)</td></tr><tr><td align="left" colspan="1" rowspan="1">p-value</td><td align="left" colspan="1" rowspan="1">p&#8201;=&#8201;0.2</td><td align="left" colspan="1" rowspan="1">p&#8201;=&#8201;0.4</td></tr><tr><td align="left" colspan="1" rowspan="1">Gender</td><td align="left" colspan="1" rowspan="1">11.4&#160;m(95% CI 4.8&#8211;11.43)</td><td align="left" colspan="1" rowspan="1">6.06&#160;m (95% CI 3.5&#8211;16.7)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Female</td><td align="left" colspan="1" rowspan="1">16.3&#160;m(95% CI 3.8&#8211;17.8)</td><td align="left" colspan="1" rowspan="1">5.9&#160;m (95% CI 0.3&#8211;12)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Male</td><td align="left" colspan="1" rowspan="1">p&#8201;=&#8201;0.1</td><td align="left" colspan="1" rowspan="1">p&#8201;=&#8201;0.1</td></tr><tr><td align="left" colspan="1" rowspan="1">Smoking Status</td><td align="left" colspan="1" rowspan="1">11.6&#160;m (95%CI8.8&#8211;17.6)</td><td align="left" colspan="1" rowspan="1">5.8&#160;m (95% CI 2.7&#8211;16.7)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Ever</td><td align="left" colspan="1" rowspan="1">16.3&#160;m (95% CI 3.6&#8211;17.8)</td><td align="left" colspan="1" rowspan="1">5.9&#160;m (95% CI 1.9&#8211;13.8)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Never</td><td align="left" colspan="1" rowspan="1">p&#8201;=&#8201;0.9</td><td align="left" colspan="1" rowspan="1">p&#8201;=&#8201;0.7</td></tr><tr><td align="left" colspan="1" rowspan="1">Brain Metastases</td><td align="left" colspan="1" rowspan="1">11.4&#160;m (95% CI 4.9&#8211;17)</td><td align="left" colspan="1" rowspan="1">5.4&#160;m (95% CI 2.7&#8211;16.9)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Present at any time</td><td align="left" colspan="1" rowspan="1">17.8&#160;m (95% CI 11.2&#8211;22)</td><td align="left" colspan="1" rowspan="1">5.9&#160;m (95% CI 2.7&#8211;13.7)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Absent</td><td align="left" colspan="1" rowspan="1">p&#8201;=&#8201;0.1</td><td align="left" colspan="1" rowspan="1">p&#8201;=&#8201;0.9</td></tr><tr><td align="left" colspan="1" rowspan="1">Histology</td><td align="left" colspan="1" rowspan="1">NR (95%CI11.-NR)</td><td align="left" colspan="1" rowspan="1">5.9&#160;m (95% CI 3.6&#8211;16.9)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Adenocarcinoma</td><td align="left" colspan="1" rowspan="1">11.4 (95%CI3.7&#8211;17.8)</td><td align="left" colspan="1" rowspan="1">3.7&#160;m (95% CI 0.3&#8211;13.9)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Squamous (including adenosquamous)</td><td align="left" colspan="1" rowspan="1">p&#8201;=&#8201;0.8</td><td align="left" colspan="1" rowspan="1">p&#8201;=&#8201;0.2</td></tr><tr><td align="left" colspan="1" rowspan="1">Co-mutations</td><td align="left" colspan="1" rowspan="1">11.9&#160;m (95%CI3.6&#8211;11.3)</td><td align="left" colspan="1" rowspan="1">5.9&#160;m (95% CI 4.7&#8211;16.7)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;TP53 present</td><td align="left" colspan="1" rowspan="1">16.4&#160;m (95%CI4.8&#8211;17)</td><td align="left" colspan="1" rowspan="1">3.5&#160;m (95% CI 1.9&#8211;9.2)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;TP53 absent</td><td align="left" colspan="1" rowspan="1">p&#8201;=&#8201;0.06</td><td align="left" colspan="1" rowspan="1">p&#8201;=&#8201;0.1</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec12"><title>Progression free survival (PFS)</title><p id="Par19">First line PFS of TKI treated patients was 11.9&#160;months (95% CI, 5.8&#8211;17.8&#160;months) vs. 5.9&#160;months (95% CI, 3.9&#8211;16.8&#160;months) (p&#8201;&lt;&#8201;0.002*) in the chemotherapy treated cases. (HR for TKI: 0.3295 (95% CI, 0.1630&#8211;0.6663) (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>). Presence of TP53 co-mutation and male gender was a factor affecting the 1st line PFS (p&#8201;&lt;&#8201;0.06) on multivariate analysis (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). The PFS for 2nd line TKI was 7.7&#160;months (95% CI, 2.8&#8211;14.8&#160;months) vs 4.6&#160;months (95% CI, 2.1&#8211;9.8&#160;months) for chemotherapy (HR for TKI: 0.3641 (95% CI, 0.1378&#8211;0.9616)} (p&#8201;&lt;&#8201;0.04*) (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>).<fig id="Fig2" position="float" orientation="portrait"><label>Fig.&#160;2</label><caption><p>Kaplan&#8211;Meier curve for First line Progression Free Survival in patients with MET Exon 14 mutant Metastatic Non-small cell lung cancer</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="12672_2025_1864_Fig2_HTML.jpg"/></fig><fig id="Fig3" position="float" orientation="portrait"><label>Fig.&#160;3</label><caption><p>Kaplan&#8211;Meier curve for Second line Progression Free Survival in patients with MET Exon 14 mutant Metastatic Non-small cell lung cancer</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO3" position="float" orientation="portrait" xlink:href="12672_2025_1864_Fig3_HTML.jpg"/></fig></p></sec><sec id="Sec13"><title>Overall survival (OS)</title><p id="Par20">In the patients treated with 1st line MET TKIs, median OS was not reached at the study endpoint (95% CI 9.2-NR months). Of the 14 patients included in PFS analysis, OS analysis could be done in 13 patients, as one patient dropped out of treatment and hence contributed to a missing datapoint. In comparison, it was 20.7&#160;months (95% CI18.1&#8211;36.1&#160;months) in the chemotherapy arm. Difference was not statistically significant (p&#8201;=&#8201;0.3). The estimates of survival proportion of means at 1&#160;yr and 2&#160;yr for the 1st line TKIs and systemic chemotherapy were 86%/47% and 73%/45%, respectively (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>).<fig id="Fig4" position="float" orientation="portrait"><label>Fig.&#160;4</label><caption><p>Kaplan&#8211;Meier curve for Overall Survival in patients with MET Exon 14 mutant Metastatic Non-small cell lung cancer treated with First line MET inhibitors</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO4" position="float" orientation="portrait" xlink:href="12672_2025_1864_Fig4_HTML.jpg"/></fig></p></sec><sec id="Sec14"><title>Adverse events</title><p id="Par21">Most commonly reported adverse event were peripheral edema, nausea, vomiting and raised creatinine level. Grade 3 or 4 reactions were reported in 36.73% (18/49) patients. Death from causes other than advanced NSCLC occurred during treatment in 3 patients (6.12%). The reported causes were atrial fibrillation, hepatitis, pneumonia, respiratory distress and sepsis.</p></sec></sec><sec id="Sec15"><title>Discussion</title><p id="Par22">The unmet need of a molecule for MET ex14 mutation led to accelerated approval of capmatinib in 2020 based on GEOMETRY Mono-1 study [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. This study examined the real-world experiences from two apex cancer centers in the Indian peninsula and by far represents the largest cohort from India. However, owing to the real-world nature of this study, the baseline conditions like ECOG PS and brain metastases were less favorable when compared to the trial conditions, thus resulting in deviation of response rates and outcomes (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>).<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table&#160;3</label><caption><p>Studies reporting the clinicopathologic characteristics and Outcome in NSCLC patients with MET exon 14 skipping alterations</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Clinico-pathological features</th><th align="left" colspan="1" rowspan="1">Batra et al. (Current Study)</th><th align="left" colspan="1" rowspan="1">Geometry study*[<xref ref-type="bibr" rid="CR3">3</xref>]</th><th align="left" colspan="1" rowspan="1">Recap study [<xref ref-type="bibr" rid="CR11">11</xref>]</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Age (Median) (years)</td><td align="left" colspan="1" rowspan="1">70 (Range, 39&#8211;85)</td><td align="left" colspan="1" rowspan="1">Cohort 4: 71 (Range, 49&#8211;90), Cohort 5b: 71 (Range, 57&#8211;86)</td><td align="left" colspan="1" rowspan="1">77 (Range, 48&#8211;91)</td></tr><tr><td align="left" colspan="1" rowspan="1">Sex (Female)</td><td align="left" colspan="1" rowspan="1">16/49 (32.70%)</td><td align="left" colspan="1" rowspan="1">58/97 (59.79%)</td><td align="left" colspan="1" rowspan="1">45/81 (56%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Brain metastasis</td><td align="left" colspan="1" rowspan="1">16/49 (32.70%)</td><td align="left" colspan="1" rowspan="1">14/97 (14.43%)</td><td align="left" colspan="1" rowspan="1">22/81 (27.16%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Histology</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Adenocarcinoma</td><td align="left" colspan="1" rowspan="1">33 (67.34%)</td><td align="left" colspan="1" rowspan="1">78/97 (80.41%)</td><td align="left" colspan="1" rowspan="1">63/81 (78%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Squamous Cell carcinoma</td><td align="left" colspan="1" rowspan="1">8 (16.33%)</td><td align="left" colspan="1" rowspan="1">8/97 (8.25%)</td><td align="left" colspan="1" rowspan="1">7/81 (9%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Adenosquamous Carcinoma</td><td align="left" colspan="1" rowspan="1">8 (16.33%)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">4/81 (5%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Sarcomatoid Carcinoma</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">2/81 (2%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Others</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">11/97 (11.34%) (Cohort 4/5b)</td><td align="left" colspan="1" rowspan="1">5/81 (6%)</td></tr><tr><td align="left" colspan="1" rowspan="1">PDL-1</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8201;&#160;&lt;&#8201;1%</td><td align="left" colspan="1" rowspan="1">9/49 (18.36%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">12/81 (15%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;1&#8211;49%</td><td align="left" colspan="1" rowspan="1">20/49 (40.82%)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">32/81 (40%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#8201;&gt;&#8201;49%</td><td align="left" colspan="1" rowspan="1">20/49 (40.82%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">33/81 (40%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Undetermined</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">4/81 (5%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Progression Free Survival (Median, months)</td><td align="left" colspan="1" rowspan="1">Previously treated: 7.7&#160;months (95% CI, 2.8&#8211;14.8&#160;months), Treatment Na&#239;ve: 11.9&#160;months (95% CI,&#160;5.8&#8211;17.8),</td><td align="left" colspan="1" rowspan="1">Cohort 4: 5.4 (95% CI,&#160;4.2&#8211;7.0), Cohort 5b: 12.4 (95% CI,&#160;8.2&#8211;NE)</td><td align="left" colspan="1" rowspan="1">Previously treated: 9.1&#160;months (95% CI, 3.1&#8211;15.1&#160;months), Treatment Na&#239;ve: 10.6&#160;months (95% CI, 5.5&#8211;15.7&#160;months)</td></tr><tr><td align="left" colspan="1" rowspan="1">Overall Survival (Median, months)</td><td align="left" colspan="1" rowspan="1">Treatment Na&#239;ve: NR (95%CI,&#160;9.2-NR)</td><td align="left" colspan="1" rowspan="1">Cohort 5b: 20.8 (95% CI,&#160;12.4-NE)</td><td align="left" colspan="1" rowspan="1">Overall population: 18.2 (95% CI,&#160;13.2&#8211;23.1), Treatment Na&#239;ve: NR, Previously treated: 17.2 (95% CI,&#160;6.7&#8211;27.7)</td></tr><tr><td align="left" colspan="1" rowspan="1">Intracranial Response</td><td align="left" colspan="1" rowspan="1">12/16 (75%)</td><td align="left" colspan="1" rowspan="1">12/13 (92.30%)</td><td align="left" colspan="1" rowspan="1">DCR: Overall population: 91% (95% CI,&#160;59&#8211;100), Treatment na&#239;ve: 83% (95% CI,&#160;36&#8211;100), Previously treated: 100% (95% CI,&#160;48&#8211;100)</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">DCR</italic> Disease control rate, <italic toggle="yes">PDL-1</italic> Programmed death-ligand 1</p><p><sup>*</sup>Cohort 4: Previously treated patient cohort; Cohort 5b: treatment na&#239;ve cohort</p></table-wrap-foot></table-wrap></p><p id="Par23">Table <xref rid="Tab3" ref-type="table">3</xref>. helps to characterize demographic and clinicopathological characteristics of patients with METex14 skipping NSCLC. Patients with METex14 skipping NSCLC were typically elderly (Median: 70&#160;years), with adenocarcinoma histology (67.34%). This is in contrast to characteristics associated with EGFR (Women, never smokers), or BRAF mutations (Women, never smokers), and ALK (Younger patients, never smokers) or ROS1 (Women, never smokers) rearrangements. MET ex14 skipping [<xref ref-type="bibr" rid="CR7">7</xref>]. METex14 skipping mutation was most commonly found in sarcomatoid histology. Brain, bone, and pleura metastases were reported in METex14 skipping NSCLC patients.</p><p id="Par24">Another real-world MET cohort (RECAP study) depicted 30.86% (25/81) patients with ECOG performance status &#10878;2 (vs. 18.37% in the current study), and the median age was slightly higher (77&#160;years vs. 70&#160;years). However, in terms of age, our cohort was matched with the Geometry trial cohort (Median age 71&#160;years). Proportion of women were higher in the RECAP and Geometry study in comparison to our patient cohort (Recap 56% vs. Geometry 59.79% vs. Study cohort 32.70%) [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p id="Par25">Patients with MET exon 14 skipping mutation have an unfavorable prognosis with current therapies including immunotherapy. In our study cohort, almost 40% of the patients had high PDL1 expression (&gt;&#8201;50%) which is in line with previously published literature. In MET exon 14 skipping mutated NSCLC, response rate of 16-36%&#160;to PDL-1 inhibitiors has been previously&#160;documented [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. Despite high PD-L1 expression, these patients do not benefit from immunotherapy due to lower tumor mutational burden. In addition, these patients are generally elderly and provide a challenge owing to a greater risk of toxicity from first line multi-drug chemotherapy regimens [<xref ref-type="bibr" rid="CR3">3</xref>]. When comparing PFS of capmatinib, the median PFS was 9.5&#160;months in RECAP study versus 11.3&#160;months in current study. In the RECAP study, median PFS was 10.6&#160;months (95% CI, 5.5&#8211;15.7&#160;months) in first line and 9.1&#160;months (95% CI, 3.1&#8211;15.1&#160;months) in second line setting. This may be attributable to the smaller proportion of patients receiving capmatinib. The GEOMTERY Mono 1 depicted a median PFS of 12.4&#160;months (95% CI, 8.2&#8212;Could not be ascertained) and 5.4&#160;months (95% CI, 4.2 to 7.0&#160;months) in treatment na&#239;ve and pre-treated patient cohort (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>) [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. These values are nonetheless significantly higher than current second- or third-line therapies available for NSCLC patients.</p><p id="Par26">Among patients with MET exon 14 skipping mutation, this difference in response rates and PFS between previously treated and treatment na&#239;ve patients may be explained by an overall decline in patients ECOG PS and health status during long duration of disease, as well as the development of resistant clones during first-line therapy. In addition, it is essential to consider the limited number of patients in the current study.</p><p id="Par27">Brain metastasis developed in up to 20&#8211;40% patients with stage IV NSCLC patients and a similar incidence has been reported among patients with MET exon 14 skipping mutations [<xref ref-type="bibr" rid="CR13">13</xref>&#8211;<xref ref-type="bibr" rid="CR15">15</xref>]. In Geometry study, % of brain metastasis was reported in 11&#8211;23% cases. In comparison, higher number of patients developed brain metastasis either during treatment or at baseline in our study (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>). Intracranial efficacy of Capmatinib was demonstrated in the published literature with results being identical to ours. In the RECAP cohort, excellent intracranial ORR and DCR of 46% (18% CR) and 91% respectively was reported. Similar intracranial rate of 92.31% was seen in Geometry trial cohort [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. Given the relevance of CNS control and its role in maintenance of quality of life, confirmation of these findings in larger populations is necessary.</p><p id="Par28">Additionally, TP53 has been described as the most common co-mutation to a MET exon 14 skipping genomic alteration, with an incidence of 22% in non-squamous histology who never smoked [<xref ref-type="bibr" rid="CR16">16</xref>]. In the RECAP study with 43% never-smokers, the TP53 mutation was the most frequent co-mutation found in seven patients (9%) [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. In our study, the same was 24.4% in the overall cohort. Although both Geometry and RECAP did not report statistically significant difference in outcome in terms of TP53 analysis, our study depicted presence of TP53 as an adverse factor for outcome on multivariate analysis (p&#8201;&lt;&#8201;0.06) (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>).</p><p id="Par29">Our study confirmed the known safety of MET inhibitors. No new safety signals were reported. Capmatinib showed a manageable safety profile with low discontinuation among patients. Majority of adverse events were of grade 1 or 2 and were reversible with dose adjustments. Most frequent reported adverse events were peripheral edema, GI side effects, increased creatinine levels, nausea and vomiting. Grade &#190; treatment related adverse events (TRAE) were reported in almost 1/3rd of our patient cohort. This is in contrast to corresponding 23% and 53% Grade &#190; TRAE noted in the RECAP and GEOMETRY Mono-1 trial cohort respectively.</p><p id="Par30">Current challenge for molecular oncologist is early identification of MET exon 14 skipping mutations in order to enable patients to benefit from MET inhibitors. International guidelines recommend NGS as a standard testing method for detecting rare genomic alterations including MET exon 14 skipping mutations [<xref ref-type="bibr" rid="CR18">18</xref>].</p><p id="Par31">Major limitation of the current study is its retrospective nature, small sample size, and heterogeneity with respect to data collection and detection methods. In addition, difference in routine clinical practice of the contributing centers, treatment guidelines and response assessment should be considered. Our real-world data is consistent with previously published phase II clinical data and is the first study from the Indian peninsula [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. This shall serve as a nidus to guide future research and larger datasets for rare mutations.</p></sec><sec id="Sec16"><title>Conclusion</title><p id="Par32">MET ex14 mutations have been reported in 3&#8211;4% NSCLC cases. MET ex14 mutations are seen commonly in elderly population and are associated with TP53 co-mutations. MET therapy showed clinical efficacy in MET exon 14 skipping mutation patients. The study results and the safety profile of MET inhibitors may present a new therapeutic option in our therapeutic armamentarium.</p></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author contributions</title><p>U.B: Concept, Manuscript writing, Reviewed Manuscript A.K.S: Manuscript writing, Data collection S.N.: Manuscript writing, Data Analysis A.D: Manuscript writing, Reviewed Manuscript, Data Collection M.S: Reviewed Manuscript, Figure preparation, Data collection A.BP: Statistics, Figure Preparation, Reviewed Manuscript A.M: Reviewed Manuscript, Concept, Data Collection VB: Statistics, Figure Preparation, Data collection V.N: Reviewed Manuscript, Concept, Data Collection K.P: Reviewed Manuscript, Data collection, Concept.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>Medical Data cannot be shared openly in order to protect study participants privacy. Also to avoid issues related to ethics surrounding study data sharing and patients privacy.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par33">Yes, I confirm to declare that all the material and methods in the current study were carried out in accordance with the relevant guidelines and institutional regulations.</p></notes><notes id="FPar2" notes-type="COI-statement"><title>Competing interests</title><p id="Par34">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Non-small cell lung cancer. Version 9.2021. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf">https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf</ext-link>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.6004/jnccn.2021.0058</pub-id><pub-id pub-id-type="pmcid">PMC10203822</pub-id><pub-id pub-id-type="pmid">34902832</pub-id></mixed-citation></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kontomanolis</surname><given-names>EN</given-names></name><name name-style="western"><surname>Koutras</surname><given-names>A</given-names></name><name name-style="western"><surname>Syllaios</surname><given-names>A</given-names></name><etal/></person-group><article-title>Role of oncogenes and tumor-suppressor genes in carcinogenesis: a review</article-title><source>Anticancer Res</source><year>2020</year><volume>40</volume><issue>11</issue><fpage>6009</fpage><lpage>6015</lpage><pub-id pub-id-type="doi">10.21873/anticanres.14622</pub-id><pub-id pub-id-type="pmid">33109539</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Kontomanolis EN, Koutras A, Syllaios A, et al. Role of oncogenes and tumor-suppressor genes in carcinogenesis: a review. Anticancer Res. 2020;40(11):6009&#8211;15. 10.21873/anticanres.14622.<pub-id pub-id-type="pmid">33109539</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21873/anticanres.14622</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wolf</surname><given-names>J</given-names></name><name name-style="western"><surname>Seto</surname><given-names>T</given-names></name><name name-style="western"><surname>Han</surname><given-names>JY</given-names></name><collab>GEOMETRY mono-1 Investigators</collab><etal/></person-group><article-title>Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer</article-title><source>N Engl J Med</source><year>2020</year><volume>383</volume><issue>10</issue><fpage>944</fpage><lpage>957</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2002787</pub-id><pub-id pub-id-type="pmid">32877583</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Wolf J, Seto T, Han JY, GEOMETRY mono-1 Investigators, et al. Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer. N Engl J Med. 2020;383(10):944&#8211;57. 10.1056/NEJMoa2002787.<pub-id pub-id-type="pmid">32877583</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2002787</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="other">Paik PK, Drilon A, Fan PD, et al. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov. 2015;5(8):842&#8211;9. 10.1158/2159-8290.CD-14-1467. Erratum in: Cancer Discov. 2016;6(3):330. 10.1158/2159-8290.CD-16-0199. <pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2159-8290.CD-14-1467</pub-id><pub-id pub-id-type="pmcid">PMC4658654</pub-id><pub-id pub-id-type="pmid">25971939</pub-id></mixed-citation></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Jia</surname><given-names>Y</given-names></name><name name-style="western"><surname>Stoopler</surname><given-names>MB</given-names></name><etal/></person-group><article-title>Next-generation sequencing of pulmonary sarcomatoid carcinoma reveals high frequency of actionable MET gene mutations</article-title><source>J Clin Oncol</source><year>2016</year><volume>34</volume><issue>8</issue><fpage>794</fpage><lpage>802</lpage><pub-id pub-id-type="doi">10.1200/JCO.2015.62.0674</pub-id><pub-id pub-id-type="pmid">26215952</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Liu X, Jia Y, Stoopler MB, et al. Next-generation sequencing of pulmonary sarcomatoid carcinoma reveals high frequency of actionable MET gene mutations. J Clin Oncol. 2016;34(8):794&#8211;802. 10.1200/JCO.2015.62.0674.<pub-id pub-id-type="pmid">26215952</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2015.62.0674</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reungwetwattana</surname><given-names>T</given-names></name><name name-style="western"><surname>Liang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>V</given-names></name><name name-style="western"><surname>Ou</surname><given-names>SI</given-names></name></person-group><article-title>The race to target MET exon 14 skipping alterations in non-small cell lung cancer: the Why, the How, the Who, the Unknown, and the Inevitable</article-title><source>Lung Cancer</source><year>2017</year><volume>103</volume><fpage>27</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.lungcan.2016.11.011</pub-id><pub-id pub-id-type="pmid">28024693</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Reungwetwattana T, Liang Y, Zhu V, Ou SI. The race to target MET exon 14 skipping alterations in non-small cell lung cancer: the Why, the How, the Who, the Unknown, and the Inevitable. Lung Cancer. 2017;103:27&#8211;37. 10.1016/j.lungcan.2016.11.011.<pub-id pub-id-type="pmid">28024693</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lungcan.2016.11.011</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mazieres</surname><given-names>J</given-names></name><name name-style="western"><surname>Vioix</surname><given-names>H</given-names></name><name name-style="western"><surname>Pfeiffer</surname><given-names>BM</given-names></name><etal/></person-group><article-title>MET exon 14 skipping in NSCLC: a systematic literature review of epidemiology, clinical characteristics, and outcomes</article-title><source>Clin Lung Cancer</source><year>2023</year><volume>24</volume><issue>6</issue><fpage>483</fpage><lpage>497</lpage><pub-id pub-id-type="doi">10.1016/j.cllc.2023.06.008</pub-id><pub-id pub-id-type="pmid">37451931</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Mazieres J, Vioix H, Pfeiffer BM, et al. MET exon 14 skipping in NSCLC: a systematic literature review of epidemiology, clinical characteristics, and outcomes. Clin Lung Cancer. 2023;24(6):483&#8211;97. 10.1016/j.cllc.2023.06.008.<pub-id pub-id-type="pmid">37451931</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cllc.2023.06.008</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paik</surname><given-names>PK</given-names></name><name name-style="western"><surname>Felip</surname><given-names>E</given-names></name><name name-style="western"><surname>Veillon</surname><given-names>R</given-names></name><etal/></person-group><article-title>Tepotinib in non-small-cell lung cancer with&#160;MET&#160;exon 14 skipping mutations</article-title><source>N Engl J Med</source><year>2020</year><volume>383</volume><issue>10</issue><fpage>931</fpage><lpage>943</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2004407</pub-id><pub-id pub-id-type="pmid">32469185</pub-id><pub-id pub-id-type="pmcid">PMC8422679</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Paik PK, Felip E, Veillon R, et al. Tepotinib in non-small-cell lung cancer with&#160;MET&#160;exon 14 skipping mutations. N Engl J Med. 2020;383(10):931&#8211;43. 10.1056/NEJMoa2004407.<pub-id pub-id-type="pmid">32469185</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2004407</pub-id><pub-id pub-id-type="pmcid">PMC8422679</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>XW</given-names></name><name name-style="western"><surname>Chen</surname><given-names>XR</given-names></name><name name-style="western"><surname>Rong</surname><given-names>YM</given-names></name><etal/></person-group><article-title>MET exon 14 skipping mutation, amplification and overexpression in pulmonary sarcomatoid carcinoma: a multi-center study</article-title><source>Transl Oncol</source><year>2020</year><volume>13</volume><issue>12</issue><fpage>100868</fpage><pub-id pub-id-type="doi">10.1016/j.tranon.2020.100868</pub-id><pub-id pub-id-type="pmid">32920328</pub-id><pub-id pub-id-type="pmcid">PMC7492996</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Liu XW, Chen XR, Rong YM, et al. MET exon 14 skipping mutation, amplification and overexpression in pulmonary sarcomatoid carcinoma: a multi-center study. Transl Oncol. 2020;13(12):100868. 10.1016/j.tranon.2020.100868.<pub-id pub-id-type="pmid">32920328</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tranon.2020.100868</pub-id><pub-id pub-id-type="pmcid">PMC7492996</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Socinski</surname><given-names>MA</given-names></name><name name-style="western"><surname>Pennell</surname><given-names>NA</given-names></name><name name-style="western"><surname>Davies</surname><given-names>KD</given-names></name></person-group><article-title><italic toggle="yes">MET</italic>&#160;exon 14 skipping mutations in non-small-cell lung cancer: an overview of biology, clinical outcomes, and testing considerations</article-title><source>JCO Precis Oncol</source><year>2021</year><pub-id pub-id-type="doi">10.1200/PO.20.00516</pub-id><pub-id pub-id-type="pmid">34036238</pub-id><pub-id pub-id-type="pmcid">PMC8140815</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Socinski MA, Pennell NA, Davies KD. <italic toggle="yes">MET</italic>&#160;exon 14 skipping mutations in non-small-cell lung cancer: an overview of biology, clinical outcomes, and testing considerations. JCO Precis Oncol. 2021. 10.1200/PO.20.00516.<pub-id pub-id-type="pmid">34036238</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/PO.20.00516</pub-id><pub-id pub-id-type="pmcid">PMC8140815</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hsu</surname><given-names>R</given-names></name><name name-style="western"><surname>Benjamin</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Nagasaka</surname><given-names>M</given-names></name></person-group><article-title>The development and role of capmatinib in the treatment of MET-dysregulated non-small cell lung cancer-a narrative review</article-title><source>Cancers (Basel)</source><year>2023</year><volume>15</volume><issue>14</issue><fpage>3561</fpage><pub-id pub-id-type="doi">10.3390/cancers15143561.PMID:37509224;PMCID:PMC10377299</pub-id><pub-id pub-id-type="pmid">37509224</pub-id><pub-id pub-id-type="pmcid">PMC10377299</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Hsu R, Benjamin DJ, Nagasaka M. The development and role of capmatinib in the treatment of MET-dysregulated non-small cell lung cancer-a narrative review. Cancers (Basel). 2023;15(14):3561. 10.3390/cancers15143561.PMID:37509224;PMCID:PMC10377299.<pub-id pub-id-type="pmid">37509224</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers15143561</pub-id><pub-id pub-id-type="pmcid">PMC10377299</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Illini</surname><given-names>O</given-names></name><name name-style="western"><surname>Fabikan</surname><given-names>H</given-names></name><name name-style="western"><surname>Swalduz</surname><given-names>A</given-names></name><etal/></person-group><article-title>Real-world experience with capmatinib in <italic toggle="yes">MET</italic> exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program</article-title><source>Ther Adv Med Oncol</source><year>2022</year><volume>13</volume><issue>14</issue><fpage>17588359221103206</fpage><pub-id pub-id-type="doi">10.1177/17588359221103206.PMID:35720834;PMCID:PMC9201318</pub-id><pub-id pub-id-type="pmcid">PMC9201318</pub-id><pub-id pub-id-type="pmid">35720834</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Illini O, Fabikan H, Swalduz A, et al. Real-world experience with capmatinib in <italic toggle="yes">MET</italic> exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program. Ther Adv Med Oncol. 2022;13(14):17588359221103206. 10.1177/17588359221103206.PMID:35720834;PMCID:PMC9201318.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/17588359221103206</pub-id><pub-id pub-id-type="pmcid">PMC9201318</pub-id><pub-id pub-id-type="pmid">35720834</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mazieres</surname><given-names>J</given-names></name><name name-style="western"><surname>Drilon</surname><given-names>A</given-names></name><name name-style="western"><surname>Lusque</surname><given-names>A</given-names></name><etal/></person-group><article-title>Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry</article-title><source>Ann Oncol</source><year>2019</year><volume>30</volume><fpage>1321</fpage><lpage>1328</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdz167</pub-id><pub-id pub-id-type="pmid">31125062</pub-id><pub-id pub-id-type="pmcid">PMC7389252</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Mazieres J, Drilon A, Lusque A, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019;30:1321&#8211;8.<pub-id pub-id-type="pmid">31125062</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/annonc/mdz167</pub-id><pub-id pub-id-type="pmcid">PMC7389252</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guisier</surname><given-names>F</given-names></name><name name-style="western"><surname>Dubos-Arvis</surname><given-names>C</given-names></name><name name-style="western"><surname>Vi&#241;as</surname><given-names>F</given-names></name><etal/></person-group><article-title>Efficacy and safety of anti-PD-1 immunotherapy in patients with advanced NSCLC With BRAF, HER2, or MET mutations or RET translocation: GFPC 01&#8211;2018</article-title><source>J Thorac Oncol</source><year>2020</year><volume>15</volume><fpage>628</fpage><lpage>636</lpage><pub-id pub-id-type="doi">10.1016/j.jtho.2019.12.129</pub-id><pub-id pub-id-type="pmid">31945494</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Guisier F, Dubos-Arvis C, Vi&#241;as F, et al. Efficacy and safety of anti-PD-1 immunotherapy in patients with advanced NSCLC With BRAF, HER2, or MET mutations or RET translocation: GFPC 01&#8211;2018. J Thorac Oncol. 2020;15:628&#8211;36.<pub-id pub-id-type="pmid">31945494</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jtho.2019.12.129</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ali</surname><given-names>A</given-names></name><name name-style="western"><surname>Goffin</surname><given-names>JR</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>A</given-names></name><name name-style="western"><surname>Ellis</surname><given-names>PM</given-names></name></person-group><article-title>Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases</article-title><source>Curr Oncol</source><year>2013</year><volume>20</volume><issue>4</issue><fpage>e300</fpage><lpage>e306</lpage><pub-id pub-id-type="doi">10.3747/co.20.1481</pub-id><pub-id pub-id-type="pmid">23904768</pub-id><pub-id pub-id-type="pmcid">PMC3728058</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Ali A, Goffin JR, Arnold A, Ellis PM. Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases. Curr Oncol. 2013;20(4):e300&#8211;6.<pub-id pub-id-type="pmid">23904768</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3747/co.20.1481</pub-id><pub-id pub-id-type="pmcid">PMC3728058</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>SK</given-names></name><name name-style="western"><surname>Alex</surname><given-names>D</given-names></name><name name-style="western"><surname>Bosdet</surname><given-names>I</given-names></name><name name-style="western"><surname>Hughesman</surname><given-names>C</given-names></name><name name-style="western"><surname>Karsan</surname><given-names>A</given-names></name><name name-style="western"><surname>Yip</surname><given-names>S</given-names></name><name name-style="western"><surname>Ho</surname><given-names>C</given-names></name></person-group><article-title>MET exon 14 skipping mutation positive non-small cell lung cancer: response to systemic therapy</article-title><source>Lung Cancer</source><year>2021</year><volume>154</volume><fpage>142</fpage><lpage>145</lpage><pub-id pub-id-type="doi">10.1016/j.lungcan.2021.02.030</pub-id><pub-id pub-id-type="pmid">33667719</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Wong SK, Alex D, Bosdet I, Hughesman C, Karsan A, Yip S, Ho C. MET exon 14 skipping mutation positive non-small cell lung cancer: response to systemic therapy. Lung Cancer. 2021;154:142&#8211;5. 10.1016/j.lungcan.2021.02.030.<pub-id pub-id-type="pmid">33667719</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lungcan.2021.02.030</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Awad</surname><given-names>MM</given-names></name><name name-style="western"><surname>Leonardi</surname><given-names>GC</given-names></name><name name-style="western"><surname>Kravets</surname><given-names>S</given-names></name><etal/></person-group><article-title>Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis</article-title><source>Lung Cancer</source><year>2019</year><volume>133</volume><fpage>96</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1016/j.lungcan.2019.05.011</pub-id><pub-id pub-id-type="pmid">31200835</pub-id><pub-id pub-id-type="pmcid">PMC8135929</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Awad MM, Leonardi GC, Kravets S, et al. Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis. Lung Cancer. 2019;133:96&#8211;102.<pub-id pub-id-type="pmid">31200835</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lungcan.2019.05.011</pub-id><pub-id pub-id-type="pmcid">PMC8135929</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mosele</surname><given-names>F</given-names></name><name name-style="western"><surname>Remon</surname><given-names>J</given-names></name><name name-style="western"><surname>Mateo</surname><given-names>J</given-names></name><etal/></person-group><article-title>Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group</article-title><source>Ann Oncol</source><year>2020</year><volume>31</volume><issue>11</issue><fpage>1491</fpage><lpage>1505</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2020.07.014</pub-id><pub-id pub-id-type="pmid">32853681</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Mosele F, Remon J, Mateo J, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2020;31(11):1491&#8211;505. 10.1016/j.annonc.2020.07.014.<pub-id pub-id-type="pmid">32853681</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.annonc.2020.07.014</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article></pmc-articleset>